E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
Matteo Molica,Massimo Breccia,Saveria Capria,Silvia Maria Trisolini,Roberto Foa,Elias Jabbour,Tapan M. Kadia +6 more
TL;DR: The role of CdA in the treatment of AML is discussed, summarizing the recent clinical data regarding its incorporation into the induction therapy for adult AML, and a low intensity combination of C dA and ARA‐C alternating with decitabine has shown promising results in older patients with AML.
Journal ArticleDOI
Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL)
Shilpa Paul,Koji Sasaki,J. Michael Savoy,Adam J. DiPippo,Nadya Jammal,Kayleigh Marx,Tapan M. Kadia,Guillermo Garcia-Manero,Farhad Ravandi,Hagop M. Kantarjian,Elias Jabbour +10 more
TL;DR: The aim of this study is to compare the incidence of CNS relapses in pts with Ph-positive ALL treated with 8 versus 12 ITs and found that a median of 12 prophylactic IT chemotherapies was a prognostic factor significantly associated with a decrease rate of CNS relapse.
Journal ArticleDOI
Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias
Tapan M. Kadia,Marina Konopleva,Guillermo Garcia-Manero,Christopher B. Benton,William G. Wierda,Prithviraj Bose,Musa Yilmaz,Elias Jabbour,Steven M. Kornblau,Kapil N. Bhalla,Naveen Pemmaraju,Nitin Jain,Rashmi Malla,Gautam Borthakur,Jorge E. Cortes,Farhad Ravandi,Hagop M. Kantarjian +16 more
TL;DR: An investigator-initiated phase I clinical trial to study the safety and feasibility of the oral CDK4/6 inhibitor palbociclib (palbo) alone and in rational combinations (cycle 2 onward), which found single-agent palbo was well tolerated, but has minimal single- agent activity in non-MLL rearranged R/R acute leukemia.
Journal ArticleDOI
Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib)
Preetesh Jain,Hagop M. Kantarjian,Aziz Nazha,Elias Jabbour,Alfonso Quintás-Cardama,Ohad Benjamini,Sherry Pierce,Marylou Cardenas-Turanzas,Srdan Verstovsek,Gautam Borthakur,Farhad Ravandi,Susan O'Brien,Jorge E. Cortes +12 more
TL;DR: In this paper, the authors analyzed patterns of response and their long-term impact among pts treated with 4 TKI modalities as frontline CML CP therapy, and concluded that early responses to TKI are an important predictor of long term outcome.
Journal ArticleDOI
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival
David Sanford,Courtney D. DiNardo,Guilin Tang,Jorge E. Cortes,Srdan Verstovsek,Elias Jabbour,Farhad Ravandi,Hagop M. Kantarjian,Guillermo Garcia-Manero +8 more
TL;DR: The acquisition of a Jumping translocations appears to be a late event and is associated with myelodysplasia, which was associated with a poor prognosis with apoor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.